(-)-epigallocatechin 3-gallate multiple interactions ISO RGD:1315840 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYBL1 mRNA CTD PMID:22079256 (S)-amphetamine decreases expression ISO RGD:1315841 6480464 Dextroamphetamine results in decreased expression of MYBL1 mRNA CTD PMID:12205029 (S)-amphetamine multiple interactions ISO RGD:1315841 6480464 SOD1 inhibits the reaction [Dextroamphetamine results in decreased expression of MYBL1 mRNA] CTD PMID:12205029 1,1-dichloroethene increases expression ISO RGD:1315841 6480464 vinylidene chloride results in increased expression of MYBL1 mRNA CTD PMID:26682919 1,2-dimethylhydrazine multiple interactions EXP 6480464 [APC protein affects the susceptibility to 1, 2-Dimethylhydrazine] which results in decreased expression of MYBL1 mRNA CTD PMID:27840820 1-naphthyl isothiocyanate increases expression EXP 6480464 1-Naphthylisothiocyanate results in increased expression of MYBL1 mRNA CTD PMID:30723492 17beta-estradiol multiple interactions ISO RGD:1315840 6480464 [Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of MYBL1 mRNA more ... CTD PMID:19619570 more ... 17beta-estradiol increases expression ISO RGD:1315840 6480464 Estradiol results in increased expression of MYBL1 mRNA CTD PMID:15913882 more ... 17beta-estradiol multiple interactions EXP 6480464 [bisphenol A co-treated with Estradiol] results in increased expression of MYBL1 mRNA CTD PMID:26496021 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1315840 6480464 [Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of MYBL1 mRNA CTD PMID:19619570 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1315841 6480464 Tetrachlorodibenzodioxin results in increased expression of MYBL1 mRNA CTD PMID:26290441 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1315841 6480464 Tetrachlorodibenzodioxin affects the expression of MYBL1 mRNA CTD PMID:26377647 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of MYBL1 mRNA CTD PMID:22298810 , PMID:32109520 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1315840 6480464 Tetrachlorodibenzodioxin results in decreased expression of MYBL1 mRNA CTD PMID:17517823 more ... 2-acetamidofluorene increases expression ISO RGD:1315841 6480464 2-Acetylaminofluorene results in increased expression of MYBL1 mRNA CTD PMID:21607683 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1315840 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of MYBL1 mRNA CTD PMID:28628672 4,4'-sulfonyldiphenol multiple interactions ISO RGD:1315840 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of MYBL1 mRNA CTD PMID:28628672 acetamide increases expression EXP 6480464 acetamide results in increased expression of MYBL1 mRNA CTD PMID:31881176 afimoxifene increases expression ISO RGD:1315840 6480464 afimoxifene results in increased expression of MYBL1 mRNA CTD PMID:19901195 aflatoxin B1 affects expression ISO RGD:1315840 6480464 Aflatoxin B1 affects the expression of MYBL1 protein CTD PMID:20106945 aflatoxin B1 increases expression EXP 6480464 Aflatoxin B1 results in increased expression of MYBL1 mRNA CTD PMID:23630614 , PMID:25378103 aflatoxin B1 increases expression ISO RGD:1315840 6480464 Aflatoxin B1 results in increased expression of MYBL1 mRNA CTD PMID:22100608 all-trans-retinoic acid decreases expression ISO RGD:1315841 6480464 Tretinoin results in decreased expression of MYBL1 mRNA CTD PMID:16604517 amphetamine decreases expression EXP 6480464 Amphetamine results in decreased expression of MYBL1 mRNA CTD PMID:30779732 antirheumatic drug decreases expression ISO RGD:1315840 6480464 Antirheumatic Agents results in decreased expression of MYBL1 mRNA CTD PMID:24449571 aristolochic acid multiple interactions EXP 6480464 [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of MYBL1 mRNA CTD PMID:23912714 arsenous acid decreases expression ISO RGD:1315840 6480464 Arsenic Trioxide results in decreased expression of MYBL1 mRNA CTD PMID:15725085 more ... azathioprine decreases expression ISO RGD:1315840 6480464 Azathioprine results in decreased expression of MYBL1 mRNA CTD PMID:22623647 bazedoxifene decreases expression ISO RGD:1315840 6480464 bazedoxifene results in decreased expression of MYBL1 mRNA CTD PMID:19914376 benzo[a]pyrene increases expression ISO RGD:1315841 6480464 Benzo(a)pyrene results in increased expression of MYBL1 mRNA CTD PMID:21715664 benzo[a]pyrene increases expression ISO RGD:1315840 6480464 Benzo(a)pyrene results in increased expression of MYBL1 mRNA CTD PMID:21632981 more ... benzo[a]pyrene diol epoxide I increases expression ISO RGD:1315840 6480464 7 more ... CTD PMID:26238291 bisphenol A increases expression ISO RGD:1315841 6480464 bisphenol A results in increased expression of MYBL1 mRNA CTD PMID:20739668 bisphenol A decreases expression ISO RGD:1315840 6480464 bisphenol A results in decreased expression of MYBL1 mRNA CTD PMID:29275510 bisphenol A increases expression ISO RGD:1315840 6480464 bisphenol A results in increased expression of MYBL1 mRNA CTD PMID:28711546 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of MYBL1 mRNA CTD PMID:25181051 bisphenol A multiple interactions EXP 6480464 [bisphenol A co-treated with Estradiol] results in increased expression of MYBL1 mRNA CTD PMID:26496021 bromobenzene increases expression EXP 6480464 bromobenzene results in increased expression of MYBL1 mRNA CTD PMID:32479839 chloropicrin increases expression ISO RGD:1315840 6480464 chloropicrin results in increased expression of MYBL1 mRNA CTD PMID:28476498 cisplatin multiple interactions ISO RGD:1315840 6480464 [Cisplatin co-treated with jinfukang] results in decreased expression of MYBL1 mRNA CTD PMID:27392435 clofibrate multiple interactions ISO RGD:1315841 6480464 [Clofibrate co-treated with Acetaminophen] affects the expression of MYBL1 mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of MYBL1 mRNA] CTD PMID:17585979 clomiphene decreases expression ISO RGD:1315840 6480464 Clomiphene results in decreased expression of MYBL1 mRNA CTD PMID:26865669 copper(II) sulfate decreases expression ISO RGD:1315840 6480464 Copper Sulfate results in decreased expression of MYBL1 mRNA CTD PMID:19549813 crocidolite asbestos decreases expression ISO RGD:1315840 6480464 Asbestos, Crocidolite results in decreased expression of MYBL1 mRNA CTD PMID:29523930 CU-O LINKAGE decreases expression ISO RGD:1315840 6480464 cupric oxide results in decreased expression of MYBL1 mRNA CTD PMID:22077320 cyclosporin A decreases expression ISO RGD:1315840 6480464 Cyclosporine results in decreased expression of MYBL1 mRNA CTD PMID:20106945 more ... dexamethasone multiple interactions ISO RGD:1315840 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of MYBL1 mRNA CTD PMID:28628672 diarsenic trioxide decreases expression ISO RGD:1315840 6480464 Arsenic Trioxide results in decreased expression of MYBL1 mRNA CTD PMID:15725085 more ... dichloroacetic acid increases expression ISO RGD:1315841 6480464 Dichloroacetic Acid results in increased expression of MYBL1 mRNA CTD PMID:28962523 diethylstilbestrol increases expression ISO RGD:1315840 6480464 Diethylstilbestrol results in increased expression of MYBL1 mRNA CTD PMID:26865669 dioxygen decreases expression ISO RGD:1315840 6480464 Oxygen deficiency results in decreased expression of MYBL1 mRNA CTD PMID:26516004 dioxygen multiple interactions ISO RGD:1315841 6480464 [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of MYBL1 mRNA CTD PMID:30529165 disodium selenite decreases expression ISO RGD:1315840 6480464 Sodium Selenite results in decreased expression of MYBL1 mRNA CTD PMID:18175754 dorsomorphin multiple interactions ISO RGD:1315840 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1315840 6480464 Doxorubicin results in decreased expression of MYBL1 mRNA CTD PMID:29803840 Echimidine increases expression EXP 6480464 echimidine results in increased expression of MYBL1 mRNA CTD PMID:32419051 estrone increases expression ISO RGD:1315840 6480464 Estrone results in increased expression of MYBL1 mRNA CTD PMID:26865669 ethyl methanesulfonate increases expression ISO RGD:1315840 6480464 Ethyl Methanesulfonate results in increased expression of MYBL1 mRNA CTD PMID:23649840 fenamidone increases expression ISO RGD:1315841 6480464 fenamidone results in increased expression of MYBL1 mRNA CTD PMID:27029645 folic acid decreases expression ISO RGD:1315840 6480464 Folic Acid results in decreased expression of MYBL1 mRNA CTD PMID:21867686 formaldehyde increases expression ISO RGD:1315840 6480464 Formaldehyde results in increased expression of MYBL1 mRNA CTD PMID:23649840 fulvestrant decreases expression ISO RGD:1315840 6480464 fulvestrant results in decreased expression of MYBL1 mRNA CTD PMID:26865669 furan increases expression EXP 6480464 furan results in increased expression of MYBL1 mRNA CTD PMID:25539665 furan decreases expression EXP 6480464 furan results in decreased expression of MYBL1 mRNA CTD PMID:27387713 furan increases methylation EXP 6480464 furan results in increased methylation of MYBL1 gene CTD PMID:27387713 genistein decreases expression ISO RGD:1315840 6480464 Genistein results in decreased expression of MYBL1 mRNA CTD PMID:22228119 genistein increases expression ISO RGD:1315840 6480464 Genistein results in increased expression of MYBL1 mRNA CTD PMID:26865669 geraniol decreases expression ISO RGD:1315840 6480464 geraniol results in decreased expression of MYBL1 mRNA CTD PMID:27683099 GW 4064 increases expression ISO RGD:1315841 6480464 GW 4064 results in increased expression of MYBL1 mRNA CTD PMID:26655953 Heliotrine increases expression EXP 6480464 heliotrine results in increased expression of MYBL1 mRNA CTD PMID:32419051 hexestrol increases expression ISO RGD:1315840 6480464 Hexestrol results in increased expression of MYBL1 mRNA CTD PMID:26865669 indometacin multiple interactions ISO RGD:1315840 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of MYBL1 mRNA CTD PMID:28628672 Lasiocarpine increases expression EXP 6480464 lasiocarpine results in increased expression of MYBL1 mRNA CTD PMID:32419051 lead diacetate decreases expression ISO RGD:1315841 6480464 lead acetate results in decreased expression of MYBL1 mRNA CTD PMID:22609695 lipopolysaccharide decreases expression ISO RGD:1315840 6480464 Lipopolysaccharides results in decreased expression of MYBL1 mRNA CTD PMID:18192897 mestranol increases expression ISO RGD:1315840 6480464 Mestranol results in increased expression of MYBL1 mRNA CTD PMID:26865669 methyl methanesulfonate increases expression ISO RGD:1315840 6480464 Methyl Methanesulfonate results in increased expression of MYBL1 mRNA CTD PMID:23649840 methylparaben decreases expression ISO RGD:1315840 6480464 methylparaben results in decreased expression of MYBL1 mRNA CTD PMID:31745603 N-methyl-N'-nitro-N-nitrosoguanidine increases expression ISO RGD:1315840 6480464 Methylnitronitrosoguanidine results in increased expression of MYBL1 mRNA CTD PMID:12634122 N-nitrosodiethylamine increases expression ISO RGD:1315841 6480464 Diethylnitrosamine results in increased expression of MYBL1 mRNA CTD PMID:21607683 nickel atom increases expression ISO RGD:1315840 6480464 Nickel results in increased expression of MYBL1 mRNA CTD PMID:25583101 ochratoxin A increases expression EXP 6480464 ochratoxin A results in increased expression of MYBL1 mRNA CTD PMID:30449730 paracetamol multiple interactions ISO RGD:1315841 6480464 [Clofibrate co-treated with Acetaminophen] affects the expression of MYBL1 mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of MYBL1 mRNA] CTD PMID:17585979 paracetamol increases expression ISO RGD:1315840 6480464 Acetaminophen results in increased expression of MYBL1 mRNA CTD PMID:22230336 phenylephrine increases expression EXP 6480464 Phenylephrine results in increased expression of MYBL1 mRNA CTD PMID:18158353 phenylmercury acetate decreases expression ISO RGD:1315840 6480464 Phenylmercuric Acetate results in decreased expression of MYBL1 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1315840 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYBL1 mRNA CTD PMID:27188386 phytoestrogen increases expression ISO RGD:1315840 6480464 Phytoestrogens results in increased expression of MYBL1 mRNA CTD PMID:18310284 pirinixic acid increases expression ISO RGD:1315841 6480464 pirinixic acid results in increased expression of MYBL1 mRNA CTD PMID:20813756 pirinixic acid multiple interactions ISO RGD:1315841 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of MYBL1 mRNA CTD PMID:19710929 potassium chromate decreases expression ISO RGD:1315840 6480464 potassium chromate(VI) results in decreased expression of MYBL1 mRNA CTD PMID:22079256 potassium chromate multiple interactions ISO RGD:1315840 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYBL1 mRNA CTD PMID:22079256 potassium dichromate decreases expression ISO RGD:1315841 6480464 Potassium Dichromate results in decreased expression of MYBL1 mRNA CTD PMID:23608068 quercetin increases expression ISO RGD:1315840 6480464 Quercetin results in increased expression of MYBL1 mRNA CTD PMID:21632981 raloxifene decreases expression ISO RGD:1315840 6480464 Raloxifene Hydrochloride results in decreased expression of MYBL1 mRNA CTD PMID:26865669 raloxifene multiple interactions ISO RGD:1315840 6480464 [Raloxifene Hydrochloride co-treated with Estradiol] results in decreased expression of MYBL1 mRNA CTD PMID:21185374 SB 431542 multiple interactions ISO RGD:1315840 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 senecionine increases expression EXP 6480464 senecionine results in increased expression of MYBL1 mRNA CTD PMID:32419051 Senkirkine increases expression EXP 6480464 senkirkine results in increased expression of MYBL1 mRNA CTD PMID:32419051 silicon dioxide increases expression ISO RGD:1315840 6480464 Silicon Dioxide analog results in increased expression of MYBL1 mRNA CTD PMID:25895662 silicon dioxide decreases expression ISO RGD:1315840 6480464 Silicon Dioxide analog results in decreased expression of MYBL1 mRNA CTD PMID:23806026 silver atom decreases expression ISO RGD:1315841 6480464 Silver results in decreased expression of MYBL1 mRNA CTD PMID:27131904 silver(0) decreases expression ISO RGD:1315841 6480464 Silver results in decreased expression of MYBL1 mRNA CTD PMID:27131904 sodium arsenite decreases expression ISO RGD:1315841 6480464 sodium arsenite results in decreased expression of MYBL1 mRNA CTD PMID:16014739 sodium arsenite increases expression ISO RGD:1315840 6480464 sodium arsenite results in increased expression of MYBL1 mRNA CTD PMID:17879257 , PMID:29301061 sunitinib decreases expression ISO RGD:1315840 6480464 Sunitinib results in decreased expression of MYBL1 mRNA CTD PMID:31533062 tetrachloromethane increases expression EXP 6480464 Carbon Tetrachloride results in increased expression of MYBL1 mRNA CTD PMID:31150632 tetrachloromethane increases expression ISO RGD:1315841 6480464 Carbon Tetrachloride results in increased expression of MYBL1 mRNA CTD PMID:29987408 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of MYBL1 mRNA CTD PMID:23411599 trichostatin A increases expression ISO RGD:1315840 6480464 trichostatin A results in increased expression of MYBL1 mRNA CTD PMID:24935251 trichostatin A affects expression ISO RGD:1315840 6480464 trichostatin A affects the expression of MYBL1 mRNA CTD PMID:28542535 urethane increases expression ISO RGD:1315840 6480464 Urethane results in increased expression of MYBL1 mRNA CTD PMID:28818685 valproic acid affects expression ISO RGD:1315840 6480464 Valproic Acid affects the expression of MYBL1 mRNA CTD PMID:25979313 valproic acid multiple interactions ISO RGD:1315840 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYBL1 mRNA CTD PMID:27188386 valproic acid increases expression ISO RGD:1315840 6480464 Valproic Acid results in increased expression of MYBL1 mRNA CTD PMID:19101580 more ... vorinostat increases expression ISO RGD:1315840 6480464 vorinostat results in increased expression of MYBL1 mRNA CTD PMID:27188386
Gene-Chemical Interaction Annotations
